Buspirone

The cleanest pharmaceutical anxiolytic — partial 5-HT1A agonist, non-controlled, non-sedating, non-addictive, cognitively neutral. Specifically labeled for generalized anxiety disorder; takes 2-4 weeks to reach full effect. Dylan has no current anxiety indication, so SKIP-FOR-NOW. For anxiety-prone archetypes (especially those who can't or won't use benzos or SSRIs), buspirone is the first-line pharmaceutical option.

Buspirone's pharmacology is unusual — it does NOT touch GABA-A, the receptor system that benzos, alcohol, barbiturates, and Z-drugs hit. This is the source of its clean profile (no sedation, no dependence, no abuse) AND the source of its slow onset (no acute felt anxiolytic effect; takes 2-4 weeks to clinical effect like an SSRI).

Primary mechanism:

• 5-HT1A partial agonist (presynaptic and postsynaptic). Presynaptic 5-HT1A autoreceptors on raphe neurons normally inhibit serotonin firing as a feedback brake. Buspirone's chronic agonism desensitizes these autoreceptors, removing the brake → increased net serotonergic transmission. Postsynaptic 5-HT1A activation in cortex and limbic system contributes to direct anxiolysis and modest pro-cognitive effects.
• Weak D2 partial agonist/antagonist. Theoretical contributor to mild prokinetic and possibly mood effects; clinically minor at standard doses.

Active metabolite:

• 1-PP (1-pyrimidinylpiperazine) — a major metabolite (about 6× higher plasma levels than parent compound) that is an alpha-2 adrenergic antagonist. Contributes some of the anxiolytic effect but also some of the dizziness and headaches.

Why no abuse potential:

• No GABA-A activity → no euphoria, no rapid felt effect, no dependence
• Slow onset to felt effect → no reinforcing acute experience
• This is the property that makes it underprescribed by patients (they want immediate relief, buspirone doesn't deliver it) but pharmacologically excellent for long-term anxiety management